Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 7/20 | 0.46 |
| ▸ | DAO | P14920 | 2/20 | 0.41 |
| ▸ | IDO1 | P14902 | 2/20 | 0.40 |
| ▸ | RHOC | P08134 | 2/20 | 0.38 |
| ▸ | RHOA | P61586 | 2/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.36 |
| ▸ | ACP1 | P24666 | 1/20 | 0.36 |
| ▸ | MLYCD | O95822 | 1/20 | 0.36 |
| ▸ | CES2 | O00748 | 1/20 | 0.35 |
| ▸ | XPO1 | O14980 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6682230 | 0.98 | TACR1 (0.44) | TACR1DAOIDO1RHOCRHOA | |
| SCHEMBL14334755 | 0.92 | TACR1 (0.44) | TACR1DAOIDO1RHOCRHOA | |
| Maleic Acid SCHEMBL17004012 | 0.89 | TACR1 (0.48) | TACR1RHOCRHOAMTORKMT2A | |
| SCHEMBL5543041 | 0.83 | TAAR1 (0.56) | DAOIDO1KMT2A | |
| SCHEMBL5535476 | 0.81 | TAAR1 (0.50) | KMT2A | |
| SCHEMBL568587 | 0.81 | RHOC (0.46) | TACR1DAOIDO1RHOCRHOA | |
| Hydrochloric Acid SCHEMBL3152128 | 0.79 | RHOC (0.45) | TACR1DAOIDO1RHOCRHOA | |
| Hydrochloric Acid SCHEMBL3143818 | 0.79 | RHOC (0.45) | TACR1DAOIDO1RHOCRHOA | |
| SCHEMBL1838112 | 0.79 | DAO (0.45) | TACR1DAOIDO1MTORCES2 | |
| SCHEMBL2895602 | 0.75 | KMT2A (0.47) | TACR1DAOIDO1KMT2APAX8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3377064-A1 | ORVEPITANT FOR THE TREATMENT OF CHRONIC COUGH | NeRRe Therapeutics Limited (GB) | 2018-09-26 | — | — | EP | claimed |
| WO-2017118584-A1 | ORVEPITANT FOR THE TREATMENT OF CHRONIC COUGH | NERRE THERAPEUTICS LIMITED (GB) | 2017-07-13 | — | — | WO | claimed |
| EP-2906219-A1 | NOVEL USES | NeRRe Therapeutics Limited (GB) | 2015-08-19 | — | — | EP | claimed |
| WO-2012175434-A1 | PHARMACEUTICAL FORMULATIONS COMPRISING VESTIPITANT | GLAXO GROUP LIMITED (GB) | 2012-12-27 | — | — | WO | claimed |
| EP-1472243-A1 | PIPERIDINE DERIVATIVES AND THEIR USE AS ANTAGONISTS OF TACHYKININS | GLAXO GROUP LIMITED (GB) | 2004-11-03 | — | — | EP | claimed |
| EP-1377558-A1 | [1,4]-DIAZEPANE-1-CARBOXYLIC ACID DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS TACHYKININ ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2004-01-07 | — | — | EP | claimed |
| WO-2003066621-A1 | PIPERIDINE DERIVATIVES AND THEIR USE AS ANTAGONISTS OF TACHYKININS | GLAXO GROUP LIMITED (GB) | 2003-08-14 | — | — | WO | claimed |
| WO-2002081457-A1 | `1,4!-DIAZEPANE-1-CARBOXYLIC ACID DERIVATIVES PROCESS FOR THEIR PREPARATION AND THEIR USE AS TACHYKININ ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2002-10-17 | — | — | WO | claimed |
| US-11813248-B2 | NK-1 antagonist compositions and methods for use in treating depression | CHASE THERAPEUTICS CORPORATION (US) | 2023-11-14 | — | — | US | disclosed |
| WO-2023111938-A1 | PROTECTION AGAINST ARTHROPOD PARASITES WITH PURINERGIC RECEPTOR (OPR) ANTAGONISTS | GURBA, Alexandre (CH) | 2023-06-22 | — | — | WO | disclosed |
| US-20220168281-A1 | NK-1 ANTAGONIST COMPOSITIONS AND METHODS FOR USE IN TREATING DEPRESSION | CHASE THERAPEUTICS CORPORATION (US) | 2022-06-02 | — | — | US | disclosed |
| US-20220160683-A1 | NK-1 ANTAGONIST COMPOSITIONS AND METHODS FOR USE IN TREATING DEPRESSION | CHASE THERAPEUTICS CORPORATION (US) | 2022-05-26 | — | — | US | disclosed |
| US-20210393595-A1 | ANTI-NEURODEGENERATIVE COMBINATIONS AND USE FOR TREATMENT OF NEURODEGENERATIVE DISEASES | CHASE THERAPEUTICS CORPORATION (US) | 2021-12-23 | — | — | US | disclosed |
| EP-3735237-A1 | USE OF (1S,3S)-3-AMINO-4-(DIFLUOROMETHYLIDENE) CYCLOPENTANE-1-CARBOXYLIC ACID AND (S)-3-AMINO-4-(DIFLUOROMETHYLENYL)CYCLOPENT-1-ENE-1-CARBOXYLIC ACID IN THE TREATMENT OF TINNITUS, ACUTE SENSORINEURAL HEARING LOSS, MENIERE'S DISEASE, TOURETTE'S SYNDROME, ATTENTION DEFICIT HYPERACTIVITY DISORDER AND ADDICTION | Ovid Therapeutics Inc. (US) | 2020-11-11 | — | — | EP | disclosed |
| EP-1472256-A1 | PIPERIDINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2004-11-03 | — | — | EP | disclosed |
| EP-1377558-A1 | [1,4]-DIAZEPANE-1-CARBOXYLIC ACID DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS TACHYKININ ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2004-01-07 | — | — | EP | disclosed |
| WO-2003066635-A1 | PIPERIDINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2003-08-14 | — | — | WO | disclosed |
| WO-2003066621-A1 | PIPERIDINE DERIVATIVES AND THEIR USE AS ANTAGONISTS OF TACHYKININS | GLAXO GROUP LIMITED (GB) | 2003-08-14 | — | — | WO | disclosed |
| WO-2003066589-A1 | PIPERIDYLCARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF TACHYKINIM-MEDIATED DISEASES | GLAXO GROUP LIMITED (GB) | 2003-08-14 | — | — | WO | disclosed |
| WO-2002081457-A1 | `1,4!-DIAZEPANE-1-CARBOXYLIC ACID DERIVATIVES PROCESS FOR THEIR PREPARATION AND THEIR USE AS TACHYKININ ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2002-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210393595-A1 | ANTI-NEURODEGENERATIVE COMBINATIONS AND USE FOR TREATMENT OF NEURODEGENERATIVE DISEASES | HTT, PARK7, SNCA | TACR1 418/4885DAO 2427/4885IDO1 287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.